PRAMEF34P

Across TCGA pan-cancer cohorts, PRAMEF34P RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated PRAMEF34P data layer.

The strongest signal is observed in kidney chromophobe (KICH), where higher PRAMEF34P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRAMEF34P expression acts as an unfavorable survival marker.

KICH, SARC, and GBM are the cancer types where PRAMEF34P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Tertile	All	0.043	0.971	<.001	99	view →
SARC	DFS	Tertile	All	0.130	0.635	<.001	36	view →
GBM	DFS	Tertile	All	0.061	0.288	<.001	18	view →
ESCA	DFS	Tertile	III,IV	0.023	0.443	<.001	18	view →
HNSC	OS	Tertile	II,III,IV	0.216	0.600	.048	9	view →
COAD	DFS	Tertile	All	0.185	0.688	.030	9	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRAMEF34P–KICH (DFS)

Open the KICH breakdown →